DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1358894
Drug: Placebo

First Posted Date: 2019-04-05

Last Posted Date: 2025-03-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT03904576

Locations: 🇳🇱
ICON, Groningen, Netherlands

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1358894 (B)
Drug: BI 1358894 (C)
Drug: BI 1358894 (D)
Drug: BI 1358894 (E)
Drug: BI 1358894 (A)

First Posted Date: 2019-03-27

Last Posted Date: 2025-02-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT03892616

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1291583 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1291583
Drug: Itraconazole

First Posted Date: 2019-03-26

Last Posted Date: 2021-11-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT03890887

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study

Phase 2

Active, not recruiting

Conditions: Generalized Pustular Psoriasis

Interventions: Drug: Spesolimab

First Posted Date: 2019-03-22

Last Posted Date: 2025-04-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 132

Registration Number: NCT03886246

Locations: 🇩🇪
Charite Universitätsmedizin Berlin KöR, Berlin, Germany
🇺🇸
Oakland Hills Dermatology, Auburn Hills, Michigan, United States
🇨🇳
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China

and more 54 locations

A Study in Healthy Men and Women to Test if Taking Different Formulations of BI 730357 Tablets Influences the Amount of BI 730357 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 730357 (Reference)
Drug: BI 730357 (Test)

First Posted Date: 2019-03-22

Last Posted Date: 2023-07-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 43

Registration Number: NCT03886272

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study About How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated in Healthy Japanese Men

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Dose group 1 - 50 mg BI 1358894
Drug: Dose group 2 - 100 mg BI 1358894
Drug: Dose group 3 - 200 mg BI 1358894

First Posted Date: 2019-03-14

Last Posted Date: 2025-02-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT03875001

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

A Study in Healthy Men to Test Whether Food Affects the Amount of BI 894416 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 894416

First Posted Date: 2019-03-12

Last Posted Date: 2023-08-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT03871595

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: BI 1291583
Drug: Placebo

First Posted Date: 2019-03-11

Last Posted Date: 2021-11-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT03868540

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)

Phase 1

Completed

Conditions: Wet Macular Degeneration

Interventions: Drug: BI 836880

First Posted Date: 2019-03-04

Last Posted Date: 2024-11-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 43

Registration Number: NCT03861234

Locations: 🇺🇸
Verum Research, LLC, Eugene, Oregon, United States
🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
🇺🇸
Retina Consultants of Texas, Bellaire, Texas, United States

and more 11 locations

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: BI 425809
Drug: Placebo

First Posted Date: 2019-03-01

Last Posted Date: 2023-11-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 200

Registration Number: NCT03859973

Locations: 🇨🇦
Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada
🇫🇷
HOP Saint-Jacques, Nantes, France
🇺🇸
Center for Behavioral Medicine, Kansas City, Missouri, United States

and more 46 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy